These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31574421)

  • 21. New Psychoactive Substances: A Matter of Time.
    Pantano F; Graziano S; Pacifici R; Busardò FP; Pichini S
    Curr Neuropharmacol; 2019; 17(9):818-822. PubMed ID: 31577198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New psychoactive substances on dark web markets: From deal solicitation to forensic analysis of purchased substances.
    Jurásek B; Čmelo I; Svoboda J; Čejka J; Svozil D; Kuchař M
    Drug Test Anal; 2021 Jan; 13(1):156-168. PubMed ID: 32678972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single chemical entity legal highs: assessing the risk for long term harm.
    McNabb CB; Russell BR; Caprioli D; Nutt DJ; Gibbons S; Dalley JW
    Curr Drug Abuse Rev; 2012 Dec; 5(4):304-19. PubMed ID: 23244343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project.
    Helander A; Bäckberg M; Hultén P; Al-Saffar Y; Beck O
    Forensic Sci Int; 2014 Oct; 243():23-9. PubMed ID: 24726531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
    Gray R; Bressington D; Hughes E; Ivanecka A
    J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014.
    Neicun J; Yang JC; Shih H; Nadella P; van Kessel R; Negri A; Czabanowska K; Brayne C; Roman-Urrestarazu A
    PLoS One; 2020; 15(10):e0241056. PubMed ID: 33125395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Public health surveillance of new psychoactive substances: recent developments.
    Fitzgerald ND; Cottler LB; Palamar JJ
    Curr Opin Psychiatry; 2024 Jul; 37(4):270-276. PubMed ID: 38587019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using internet snapshot surveys to enhance our understanding of the availability of the novel psychoactive substance 4-methylaminorex and 4,4'-dimethylaminorex.
    Nizar H; Dargan PI; Wood DM
    J Med Toxicol; 2015 Mar; 11(1):80-4. PubMed ID: 25167967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sudden cardiac death associated to substances of abuse and psychotropic drugs consumed by young people: A population study based on forensic autopsies.
    Morentin B; Callado LF
    Drug Alcohol Depend; 2019 Aug; 201():23-28. PubMed ID: 31174141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prohibition is a key driver of the new psychoactive substances (NPS) phenomenon.
    Rolles S; Kushlick D
    Addiction; 2014 Oct; 109(10):1589-90. PubMed ID: 25163705
    [No Abstract]   [Full Text] [Related]  

  • 31. The challenge of complex drug use: Associated use of codeine-containing medicines and new psychoactive substances in a European cross-sectional online population.
    Kimergård A; Foley M; Davey Z; Wadsworth E; Drummond C; Deluca P
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28597537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New/emerging psychoactive substances and associated psychopathological consequences.
    Schifano F; Napoletano F; Chiappini S; Guirguis A; Corkery JM; Bonaccorso S; Ricciardi A; Scherbaum N; Vento A
    Psychol Med; 2021 Jan; 51(1):30-42. PubMed ID: 31327332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics in new psychoactive substance users: A single center study.
    Su YJ; Chen TH; Liao WH; Chang KS; Lai YC
    Medicine (Baltimore); 2023 Jun; 102(25):e34084. PubMed ID: 37352073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A 3-year review of new psychoactive substances in casework.
    Elliott S; Evans J
    Forensic Sci Int; 2014 Oct; 243():55-60. PubMed ID: 24810679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global strategy for New Psychoactive Substances: an update.
    Vicknasingam B; Narayanan S; Singh D; Corazza O
    Curr Opin Psychiatry; 2020 Jul; 33(4):295-300. PubMed ID: 32398543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The challenge of the novel psychoactive substances: How have we responded and what are the implications of this response?
    Wood DM; Dargan PI
    Br J Clin Pharmacol; 2020 Mar; 86(3):407-409. PubMed ID: 32144815
    [No Abstract]   [Full Text] [Related]  

  • 37. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
    Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
    [No Abstract]   [Full Text] [Related]  

  • 38. Screening method for rapid classification of psychoactive substances in illicit tablets using mid infrared spectroscopy and PLS-DA.
    Pereira LSA; Lisboa FLC; Coelho Neto J; Valladão FN; Sena MM
    Forensic Sci Int; 2018 Jul; 288():227-235. PubMed ID: 29777946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.
    Santos-Toscano R; Guirguis A; Davidson C
    Br J Clin Pharmacol; 2020 Mar; 86(3):452-481. PubMed ID: 32045495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New psychoactive substances: challenges for drug surveillance, control, and public health responses.
    Peacock A; Bruno R; Gisev N; Degenhardt L; Hall W; Sedefov R; White J; Thomas KV; Farrell M; Griffiths P
    Lancet; 2019 Nov; 394(10209):1668-1684. PubMed ID: 31668410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.